Neurocrine Biosciences, Inc. (NBIX) Ownership
NBIX ownership summary
as of October 18, 2026- Institutions
- 103.3% of shares outstanding
- Insiders
- 1.06% of shares outstanding
- Shares outstanding
- 101.6M
- Float
- 100.4M shares available to trade
- Short interest
- 7.48% 5.9M shares short
- Days to cover
- 4.67 short interest up 17.9% vs prior month
- Institutions 103.33%
- Insiders 1.06%
NBIX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 13.49% | 13.7M | $1.86B | +326,000 (+2.4%) | June 30, 2026 |
| 2 | JPMorgan Chase & Co | 6.29% | 6.4M | $868.4M | +956,607 (+17.6%) | June 30, 2026 |
| 3 | Dodge & Cox | 5.49% | 5.6M | $757.9M | +123,670 (+2.3%) | June 30, 2026 |
| 4 | Vanguard Portfolio Management, LLC | 4.89% | 5.0M | $675.0M | +247,739 (+5.2%) | June 30, 2026 |
| 5 | Vanguard Capital Management, LLC | 4.47% | 4.5M | $616.8M | +33,435 (+0.7%) | June 30, 2026 |
| 6 | State Street Corp | 4.31% | 4.4M | $595.2M | +31,072 (+0.7%) | June 30, 2026 |
| 7 | AQR Capital Management LLC | 3.76% | 3.8M | $518.1M | −1.1M (−22.7%) | June 30, 2026 |
| 8 | Renaissance Technologies Corp | 2.30% | 2.3M | $317.0M | −83,000 (−3.4%) | June 30, 2026 |
| 9 | Geode Capital Management, LLC | 2.10% | 2.1M | $290.3M | +2,105 (+0.1%) | June 30, 2026 |
| 10 | Two Sigma Investments LLC | 2.04% | 2.1M | $281.8M | −984,310 (−32.2%) | June 30, 2026 |
| 11 | Vestal Point Capital LP | 1.85% | 1.9M | $255.1M | +630,000 (+50.4%) | June 30, 2026 |
| 12 | BNP Paribas Investment Partners SA | 1.47% | 1.5M | $202.8M | +446 (+0.0%) | June 30, 2026 |
| 13 | Morgan Stanley - Brokerage Accounts | 1.30% | 1.3M | $178.9M | +99,411 (+8.2%) | June 30, 2026 |
| 14 | RTW INVESTMENTS, LLC | 1.25% | 1.3M | $172.1M | +205,853 (+19.4%) | June 30, 2026 |
| 15 | Northern Trust Corp | 1.24% | 1.3M | $171.0M | +16,887 (+1.4%) | June 30, 2026 |
| 16 | Amvescap Plc. | 1.06% | 1.1M | $146.2M | +721,308 (+202.6%) | June 30, 2026 |
| 17 | Charles Schwab Investment Management Inc | 0.96% | 974K | $132.2M | +71,491 (+7.9%) | June 30, 2026 |
| 18 | NORGES BANK | 0.96% | 974K | $132.2M | −173,016 (−15.1%) | June 30, 2026 |
| 19 | First Trust Advisors L.P. | 0.91% | 923K | $125.3M | −36,092 (−3.8%) | June 30, 2026 |
| 20 | Dimensional Fund Advisors, Inc. | 0.72% | 733K | $99.5M | +21,115 (+3.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 3.5M shares and 5 cut 2.4M.
NBIX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Dodge & Cox Stock I | 3.90% | 4.0M | $538.0M | — | June 30, 2026 |
| 2 | iShares Core S&P Mid-Cap ETF | 3.56% | 3.6M | $491.4M | −1,296 (−0.0%) | September 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 3.15% | 3.2M | $434.2M | −3,515 (−0.1%) | August 31, 2026 |
| 4 | Vanguard Small Cap Index | 2.25% | 2.3M | $310.5M | −25,442 (−1.1%) | September 30, 2026 |
| 5 | Vanguard MStar Small Cap Growth Indx Inv | 1.25% | 1.3M | $172.7M | −55,037 (−4.1%) | September 30, 2026 |
| 6 | State Street® SPDR® S&P® Biotech ETF | 0.94% | 959K | $130.1M | −18,250 (−1.9%) | September 30, 2026 |
| 7 | JPMorgan Mid Cap Growth I | 0.90% | 917K | $124.5M | +53,329 (+6.2%) | August 31, 2026 |
| 8 | JPMorgan Growth Advantage A | 0.81% | 824K | $111.8M | −151,415 (−15.5%) | August 31, 2026 |
| 9 | iShares Biotechnology ETF | 0.77% | 784K | $106.4M | −5,936 (−0.8%) | September 30, 2026 |
| 10 | State Street® SPDR® S&P MIDCAP 400® ETF | 0.74% | 752K | $102.0M | +16,250 (+2.2%) | September 30, 2026 |
| 11 | VictoryShares Free Cash Flow ETF | 0.69% | 699K | $94.8M | +495 (+0.1%) | September 30, 2026 |
| 12 | iShares MSCI USA Min Vol Factor ETF | 0.68% | 690K | $93.7M | — | September 30, 2026 |
| 13 | Invesco S&P MidCap Quality ETF | 0.66% | 668K | $90.6M | +695 (+0.1%) | September 30, 2026 |
| 14 | Vanguard Explorer Inv | 0.63% | 638K | $86.5M | +154,270 (+31.9%) | June 30, 2026 |
| 15 | iShares S&P Mid-Cap 400 Growth ETF | 0.58% | 587K | $79.6M | −626 (−0.1%) | September 30, 2026 |
| 16 | State Street SPDR Port S&P 400 Md CpETF | 0.53% | 537K | $72.9M | −752 (−0.1%) | September 30, 2026 |
| 17 | First Trust NYSE Arca Biotech ETF | 0.50% | 511K | $69.4M | — | September 30, 2026 |
| 18 | Fidelity Extended Market Index | 0.48% | 490K | $66.4M | −5,439 (−1.1%) | August 31, 2026 |
| 19 | iShares Russell Mid-Cap Growth ETF | 0.47% | 479K | $65.0M | −513 (−0.1%) | September 30, 2026 |
| 20 | Vanguard Capital Opportunity Inv | 0.41% | 416K | $56.5M | −1,000 (−0.2%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
NBIX insider transactions
latest 15| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-16 | Kyle Gano | Sell | $132.70 | 36,400 | $4.8M |
| 2025-12-16 | Leslie V Norwalk | Sell | $155.09 | 1,190 | $184,557 |
| 2025-12-15 | Leslie V Norwalk | Sell | $152.23 | 5,000 | $761,150 |
| 2025-12-08 | Darin Lippoldt | Sell | $159.65 | 4,376 | $698,628 |
| 2025-11-25 | George J Morrow | Sell | $143.37 | 15,000 | $2.2M |
| 2025-11-05 | William H Rastetter | Sell | $151.82 | 18,000 | $2.7M |
| 2025-11-04 | Kyle Gano | Sell | $141.97 | 300 | $42,591 |
| 2025-08-07 | Kevin Charles Gorman | Sell | $126.41 | 106,322 | $13.4M |
| 2025-07-10 | Ingrid Delaet | Sell | $135.00 | 457 | $61,695 |
| 2025-07-09 | Jude Onyia | Sell | $130.46 | 59,819 | $7.8M |
| 2025-07-02 | Jude Onyia | Sell | $130.13 | 20,362 | $2.6M |
| 2025-06-17 | Lisa C. McClain | Sell | $124.88 | — | — |
| 2025-06-11 | Lisa C. McClain | Buy | $124.17 | — | — |
| 2025-05-27 | Kevin Charles Gorman | Sell | $120.38 | 9,613 | $1.2M |
| 2025-05-05 | William H Rastetter | Sell | $110.20 | 30,000 | $3.3M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
NBIX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns NBIX
Institutional investors own 103.3% of Neurocrine Biosciences's shares and insiders 1.06%. The largest holder is BlackRock Inc with 13.49% of the shares (13.7M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 5 reduced their stake in the latest filings. Short interest is 7.48% of the float, or 4.67 days of average trading volume. The share count rose 34.6% since 2014.
Related: NBIX analyst forecast, NBIX key metrics. See the NBIX stock overview for the latest quote and news.
NBIX ownership FAQ
Who owns the most Neurocrine Biosciences stock?
The largest shareholders of Neurocrine Biosciences are BlackRock Inc (13.49%), JPMorgan Chase & Co (6.29%), Dodge & Cox (5.49%), Vanguard Portfolio Management, LLC (4.89%), Vanguard Capital Management, LLC (4.47%).
What percentage of Neurocrine Biosciences is owned by institutions?
Institutions hold 103.3% of Neurocrine Biosciences's shares outstanding; insiders hold 1.06%.
Which funds own Neurocrine Biosciences?
The largest fund holders of Neurocrine Biosciences are Dodge & Cox Stock I (3.90%), iShares Core S&P Mid-Cap ETF (3.56%), Vanguard MStar Total Stk Mkt Idx Invest (3.15%), Vanguard Small Cap Index (2.25%), Vanguard MStar Small Cap Growth Indx Inv (1.25%).
What is Neurocrine Biosciences's short interest?
5.9M shares of Neurocrine Biosciences were sold short, 7.48% of the float; at the average daily volume it would take 4.67 days to cover.
Are insiders buying or selling Neurocrine Biosciences?
Of the latest 15 reported insider transactions in Neurocrine Biosciences (since May 5, 2025), 1 were purchases and 14 were sales.
How many shares of Neurocrine Biosciences are outstanding?
Neurocrine Biosciences has 101.6M shares outstanding, of which 100.4M are in the public float.